Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 185

1.

An anti-TNFR1 scFv-HSA fusion protein as selective antagonist of TNF action.

Berger V, Richter F, Zettlitz K, Unverdorben F, Scheurich P, Herrmann A, Pfizenmaier K, Kontermann RE.

Protein Eng Des Sel. 2013 Oct;26(10):581-7. doi: 10.1093/protein/gzt044. Epub 2013 Sep 4.

PMID:
24006371
2.

A humanized tumor necrosis factor receptor 1 (TNFR1)-specific antagonistic antibody for selective inhibition of tumor necrosis factor (TNF) action.

Kontermann RE, Münkel S, Neumeyer J, Müller D, Branschädel M, Scheurich P, Pfizenmaier K.

J Immunother. 2008 Apr;31(3):225-34. doi: 10.1097/CJI.0b013e31816a88f9.

PMID:
18317365
3.

ATROSAB, a humanized antagonistic anti-tumor necrosis factor receptor one-specific antibody.

Zettlitz KA, Lorenz V, Landauer K, Münkel S, Herrmann A, Scheurich P, Pfizenmaier K, Kontermann R.

MAbs. 2010 Nov-Dec;2(6):639-47. Epub 2010 Nov 1.

4.

Construction of an anti-IL-1β scfv and TNFRI fusion protein and its therapeutic effect on RA mice model.

Kan F, Ren G, Guo M, Qi J, Zhang Y, Han Y, Zhang Y, Li D.

Curr Pharm Biotechnol. 2014;14(12):1048-61.

PMID:
24433504
5.

Pharmacokinetic and Pharmacodynamic Characterisation of an Anti-Mouse TNF Receptor 1 Domain Antibody Formatted for In Vivo Half-Life Extension.

Goodall LJ, Ovecka M, Rycroft D, Friel SL, Sanderson A, Mistry P, Davies ML, Stoop AA.

PLoS One. 2015 Sep 9;10(9):e0137065. doi: 10.1371/journal.pone.0137065. eCollection 2015.

6.

Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin.

Müller D, Karle A, Meissburger B, Höfig I, Stork R, Kontermann RE.

J Biol Chem. 2007 Apr 27;282(17):12650-60. Epub 2007 Mar 8.

7.

Antagonistic TNF receptor one-specific antibody (ATROSAB): receptor binding and in vitro bioactivity.

Richter F, Liebig T, Guenzi E, Herrmann A, Scheurich P, Pfizenmaier K, Kontermann RE.

PLoS One. 2013 Aug 19;8(8):e72156. doi: 10.1371/journal.pone.0072156. eCollection 2013.

8.

Fusion of HSA influences TNF-α neutralizing activity of shTNFRs.

Zhan J, Chen Y, Yuan HY, Li H, Lu H.

Biotechnol Lett. 2012 Mar;34(3):417-23. doi: 10.1007/s10529-011-0793-3. Epub 2011 Nov 15.

PMID:
22083716
9.
10.

Secretion from bacterial versus mammalian cells yields a recombinant scFv with variable folding properties.

Vendel MC, Favis M, Snyder WB, Huang F, Capili AD, Dong J, Glaser SM, Miller BR, Demarest SJ.

Arch Biochem Biophys. 2012 Oct 15;526(2):188-93. doi: 10.1016/j.abb.2011.12.018. Epub 2012 Jan 2.

PMID:
22230329
11.

Recombinant 55-kDa tumor necrosis factor (TNF) receptor. Stoichiometry of binding to TNF alpha and TNF beta and inhibition of TNF activity.

Loetscher H, Gentz R, Zulauf M, Lustig A, Tabuchi H, Schlaeger EJ, Brockhaus M, Gallati H, Manneberg M, Lesslauer W.

J Biol Chem. 1991 Sep 25;266(27):18324-9.

12.

TNF-Selectokine: a novel prodrug generated for tumor targeting and site-specific activation of tumor necrosis factor.

Wüest T, Gerlach E, Banerjee D, Gerspach J, Moosmayer D, Pfizenmaier K.

Oncogene. 2002 Jun 20;21(27):4257-65.

13.

Single-chain variable fragment albumin fusions bind the neonatal Fc receptor (FcRn) in a species-dependent manner: implications for in vivo half-life evaluation of albumin fusion therapeutics.

Andersen JT, Cameron J, Plumridge A, Evans L, Sleep D, Sandlie I.

J Biol Chem. 2013 Aug 16;288(33):24277-85. doi: 10.1074/jbc.M113.463000. Epub 2013 Jul 1.

14.

Superior serum half life of albumin tagged TNF ligands.

Müller N, Schneider B, Pfizenmaier K, Wajant H.

Biochem Biophys Res Commun. 2010 Jun 11;396(4):793-9. doi: 10.1016/j.bbrc.2010.04.134. Epub 2010 May 4.

PMID:
20447380
15.

Structure-function relationship of tumor necrosis factor (TNF) and its receptor interaction based on 3D structural analysis of a fully active TNFR1-selective TNF mutant.

Mukai Y, Shibata H, Nakamura T, Yoshioka Y, Abe Y, Nomura T, Taniai M, Ohta T, Ikemizu S, Nakagawa S, Tsunoda S, Kamada H, Yamagata Y, Tsutsumi Y.

J Mol Biol. 2009 Jan 30;385(4):1221-9. doi: 10.1016/j.jmb.2008.11.053. Epub 2008 Dec 6.

PMID:
19084540
16.

VH/VL interface engineering to promote selective expression and inhibit conformational isomerization of thrombopoietin receptor agonist single-chain diabody.

Igawa T, Tsunoda H, Kikuchi Y, Yoshida M, Tanaka M, Koga A, Sekimori Y, Orita T, Aso Y, Hattori K, Tsuchiya M.

Protein Eng Des Sel. 2010 Aug;23(8):667-77. doi: 10.1093/protein/gzq034. Epub 2010 Jun 24.

PMID:
20576629
17.

Construction, purification, and characterization of anti-BAFF scFv-Fc fusion antibody expressed in CHO/dhfr- cells.

Cao M, Cao P, Yan H, Lu W, Ren F, Hu Y, Zhang S.

Appl Biochem Biotechnol. 2009 Jun;157(3):562-74. doi: 10.1007/s12010-008-8434-6. Epub 2008 Dec 20.

PMID:
19099209
18.

Half-life extension of a single-chain diabody by fusion to domain B of staphylococcal protein A.

Unverdorben F, Färber-Schwarz A, Richter F, Hutt M, Kontermann RE.

Protein Eng Des Sel. 2012 Feb;25(2):81-8. doi: 10.1093/protein/gzr061. Epub 2012 Jan 11.

PMID:
22238430
19.

Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC.

Repp R, Kellner C, Muskulus A, Staudinger M, Nodehi SM, Glorius P, Akramiene D, Dechant M, Fey GH, van Berkel PH, van de Winkel JG, Parren PW, Valerius T, Gramatzki M, Peipp M.

J Immunol Methods. 2011 Oct 28;373(1-2):67-78. doi: 10.1016/j.jim.2011.08.003. Epub 2011 Aug 9.

PMID:
21855548
20.

Production in yeast of pseudotype virus-like particles harboring functionally active antibody fragments neutralizing the cytolytic activity of vaginolysin.

Pleckaityte M, Zvirbliene A, Sezaite I, Gedvilaite A.

Microb Cell Fact. 2011 Dec 15;10:109. doi: 10.1186/1475-2859-10-109.

Supplemental Content

Support Center